注射用利培酮微球治疗精神分裂症的疗效及安全性观察  

Efficacy and safety of long-acting injectable risperidone in patients with schizophrenia

作　　者：陈云春[1] 谭庆荣[1] 王怀海[1] 张瑞国[1] 王化宁[1] 王志忠[1] 郭力[1] 

机构地区：[1]第四军医大学西京医院心身科,西安710032

出　　处：《中国新药杂志》2010年第5期399-402,共4页Chinese Journal of New Drugs

摘　　要：目的:探讨注射用利培酮微球治疗精神分裂症的疗效及安全性。方法:选择我院病程在1年以上的48例精神分裂症患者,给予注射用利培酮微球及口服利培酮片剂合并治疗4周,此后单一使用注射用利培酮微球维持治疗8周。采用阳性、阴性症状量表(PANSS)、临床总体印象-严重度量表(CGI-S)、和人际和社会能力量表(PSP)评定疗效,采用不良反应量表(TESS)、锥体外系症状量表、临床实验室检查、生命体征、心电图和体格检查评价安全性。结果:注射用利培酮微球单一使用8周后,其有效率(PANSS减分≥30%)为80.5%,CGI-S平均减分为2.1,PSP增加≥7分的患者比例为85.32%;注射用利培酮微球对体重影响较小,锥体外系不良反应较轻。心电图指标、生命体征及体格检查无明显改变,约7.0%(3/43)的患者出现转氨酶升高。结论:注射用利培酮微球可明显改善患者社会功能,可作为一线抗精神病药物单一使用。Objective ： To assess the efficacy and safety of long-acting injectable risperidone （LAIR） in patients with schizophrenia. Methods： A total of 48 schizophrenia patients with symptoms lasting over 1 year were collected, and treated with LAIR and oral risperidone tablets for 4 weeks followed by LAIR alone for 8 weeks. The efficacy was evaluated using the Positive and Negative Syndrome Scale （PANSS）, Clinical Global Impression Scales for severity （CGI-S） and Personal and Social Performance Scale （PSP）. The adverse reactions were evaluated using the TESS, AIMS, BARS Scale, laboratory indexes, vital signs, medical and electrocardiographic examinations. Results： After treatment with LAIR alone for 8 weeks, the total effective rate （PANSS reduced ≥30% ） was 80.5% ; mean reduction in CGI-S was 2.1; the rate of patients with increased PSP ≥7 was 85.32%. LAIR mildly affected weight-gain profile and caused less extrapyramidal reactions. There were no significant changes in vital signs, medical and electrocardiographic examinations, but 7.0% patients had an increase in glutamate pyruvate transaminase （GPT） activity. Conclusions： LAIR significantly improves the social performance in patients with schizophrenia, and can be used as the first line antipsychotic for monotherapy.

关 键 词：精神分裂症 注射用利培酮微球 非典型抗精神病药物 疗效 安全性 

分 类 号：R971.41[医药卫生—药品]